Rockwell Medical, Inc. (NASDAQ:RMTI) Sees Significant Increase in Short Interest

Rockwell Medical, Inc. (NASDAQ:RMTI) was the recipient of a significant increase in short interest in August. As of August 15th, there was short interest totaling 175,100 shares, anincreaseof72.2% from the July 31st total of 101,700 shares. Based on an average daily volume of 470,000 shares, the short-interest ratio is presently 0.4 days. Currently,0.6% of the shares of the stock are sold short. Currently,0.6% of the shares of the stock are sold short. Based on an average daily volume of 470,000 shares, the short-interest ratio is presently 0.4 days.

Rockwell Medical Price Performance

Shares of NASDAQ:RMTI opened at $1.62 on Monday. The company’s fifty day moving average is $1.14 and its two-hundred day moving average is $1.16. The company has a quick ratio of 2.51, a current ratio of 2.89 and a debt-to-equity ratio of 0.30. Rockwell Medical has a 12-month low of $0.78 and a 12-month high of $5.15. The company has a market cap of $55.78 million, a P/E ratio of -27.00 and a beta of 1.82.

Rockwell Medical (NASDAQ:RMTI) last announced its earnings results on Thursday, August 14th. The company reported ($0.05) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.05). Rockwell Medical had a negative net margin of 2.38% and a negative return on equity of 6.79%. The company had revenue of $16.07 million for the quarter, compared to the consensus estimate of $16.33 million. Rockwell Medical has set its FY 2025 guidance at EPS. Equities analysts expect that Rockwell Medical will post 0.03 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Rockwell Medical

A number of hedge funds have recently modified their holdings of RMTI. Raymond James Financial Inc. acquired a new position in shares of Rockwell Medical in the fourth quarter worth $28,000. Barclays PLC increased its position in Rockwell Medical by 27.5% during the fourth quarter. Barclays PLC now owns 28,854 shares of the company’s stock worth $59,000 after buying an additional 6,229 shares during the last quarter. Dimensional Fund Advisors LP acquired a new position in Rockwell Medical during the fourth quarter worth $146,000. Finally, Panagora Asset Management Inc. acquired a new position in Rockwell Medical during the second quarter worth $41,000. 23.31% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Wall Street Zen raised Rockwell Medical from a “sell” rating to a “hold” rating in a report on Saturday, June 14th. One analyst has rated the stock with a Strong Buy rating and two have issued a Buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $4.00.

Rockwell Medical Company Profile

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.